Adherence to HAART for management of Kaposi''s sarcoma

Adherence to HAART for management of Kaposi''s sarcoma


Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days

₹ 5,886

Availability: Out of stock


Delivery :

5% Cashback on all Orders paid using MobiKwik Wallet T&C

Free Krispy Kreme Voucher on all Orders paid using UltraCash Wallet T&C
Product Out of Stock Subscription

(Notify me when this product is back in stock)

  • Product Description

Adherence outcomes in patients with the most severe complications of AIDS, Kaposi''s sarcoma (KS), the commonest AIDS related cancer, is unknown. This books reports on 35 patients prospectively evaluated over 12 months for adherence to highly active antiretroviral therapy (HAART) in a clinical trial of ARVs for management of AIDS KS in KwaZulu- Natal (KZN). Twenty of the initial patients also recieved Chemotherapy (CXT). Adherence was assessed by 7-day self-report. Patients who reported >95% mean adherence were classified as being adherent to HAART. HIV-1 viral load (VL) and CD4+ cell counts were correlated with adherence to HAART. Mean adherence was 86%.This is the first study to show high adherence rates in patients with AIDS KS, receiving HAART, with and without chemotherapy (CTX), specifically in KwaZulu- Natal South Africa. This experience indicates that adherence to generic fixed-dose combination of stavudine, lamivudine and nevirapine is effective and hold much promise.

Product Specifications
SKU :COC94462
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
Product First Available On ClickOnCare.com2015-08-14
0 Review(s)